7-day tailored treatment to eradicate H. pylori infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Because antibiotic resistance to H. pylori has been rising in Korea, investigators compared a 7-day regimen chosen from culture and minimal inhibitory concentration (MIC) results with a standard 10-day sequential regimen. Patients with confirmed H. pylori (by rapid urease test, histology, or urea breath test) received either the tailored 7-day therapy (PPI-based triple, bismuth quadruple, or moxifloxacin-containing triple depending on susceptibility) or 10-day sequential therapy. The primary outcome was eradication success rate; investigators also measured the prevalence of antibiotic resistance in the tailored group. The trial was conducted at a single center using microbiology-guided selection to individualize therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patients who proved H. pylori infection following three methods

  1. positive rapid urease test (CLOtest)
  2. histologic evidence of H. pylori by modified Giemsa staining
  3. positive Urea breath test
* Male and female Korean Adult (Aged ≥ 18 years)

Exclusion Criteria:

* Patients who received eradication therapy for H. pylori infection, previously
* H. pylori eradication failure because of poor compliance
* the administration of antibiotics or the consumption of bismuth salts within 4 weeks or the administration of a proton pump inhibitor (PPI) within 2 weeks
* Advanced gastric cancer or other malignancy
* Abnormal liver function or liver cirrhosis
* Abnormal renal function or chronic kidney disease
* Other severe concurrent diseases
* Previous allergic reactions to the study drugs
* Pregnant or lactating women

Where it's running

• Seoul National University Bundang Hospital
  Seongnam-si, Gyeonggi-do, South Korea Recruiting

Study contacts

• Principal investigator: Nayoung Kim, M.D., Ph. D — Seoul National University Bundang Hospital
• Study coordinator: Nayoung Kim, M.D., Ph. D
• Email: nayoungkim49@empas.com
• Phone: 82-31-787-7008

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Keverprazan-Minocycline Dual Therapy vs Bismuth Quadruple Therapy for H. pylori Eradication

  This trial tests whether a keverprazan-minocycline dual therapy can eradicate Helicobacter pylori as well as or better than a bismuth-based quadruple therapy in adults who haven’t had eradication treatment before.

  Recruiting Phase 3 Nanjing First Hospital, Nanjing Medical University · Nanjing, Jiangsu · NCT07904429

• Prevalence and possible role of non-H. pylori Helicobacter species in gastric conditions and cancers

  Researchers will test stomach tissue from people with functional dyspeasia, various gastritis conditions, gastric cancer, and bariatric patients to see if non-H. pylori Helicobacter species are present.

  Recruiting at 3 sites Universiteit Antwerpen · Edegem and 2 other locations · NCT07770126

• Vonoprazan versus a proton pump inhibitor with vitamin D or probiotics added to triple antibiotics for H. pylori eradication

  This trial tests whether replacing a PPI with vonoprazan and adding vitamin D or a probiotic to standard clarithromycin–amoxicillin therapy helps adults with H. pylori infection clear the bacteria.

  Recruiting Phase 2 Tanta University · Shibīn al Kawm · NCT07293910

• Gastric cancer risk in carriers of high-risk Helicobacter pylori variants

  This study will see if people carrying high‑risk genetic subtypes of H. pylori develop gastric cancer or precancerous lesions more often than people without those subtypes.

  Recruiting Fudan University · Tongling · NCT06896370

• Fecal transplant to help eradicate stubborn Helicobacter pylori infection

  This study tests whether giving a fecal microbiota transplant can help people with Helicobacter pylori infection that has not responded to standard treatments.

  Recruiting Phase 4 Sichuan Provincial People's Hospital · Chengdu, Sichuan · NCT07704255

• Fecal-guided simplified vonoprazan plus clarithromycin first-line therapy for H. pylori

  We are testing whether a two-drug regimen of vonoprazan plus clarithromycin clears H. pylori in adults whose fecal PCR shows no clarithromycin resistance mutations.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07439445

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.